S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:NRXP

NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis

$0.47
-0.06 (-11.28%)
(As of 03/28/2024 ET)
Today's Range
$0.42
$0.54
50-Day Range
$0.29
$0.70
52-Week Range
$0.22
$1.20
Volume
2.53 million shs
Average Volume
2.82 million shs
Market Capitalization
$43.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NRx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
6.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.11mentions of NRx Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.38) to ($0.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.36 out of 5 stars

Medical Sector

904th out of 939 stocks

Pharmaceutical Preparations Industry

428th out of 444 stocks

NRXP stock logo

About NRx Pharmaceuticals Stock (NASDAQ:NRXP)

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

NRXP Stock Price History

NRXP Stock News Headlines

Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
Bombshell 2024 election documentary
2024: America’s Last Election New documentary reveals why this could be America’s Last Election… and how the elites’ plan threatens to reset the entire U.S. economy, along with your 401(k), bank, and stock portfolio.
NRXP Apr 2024 2.000 call
NRXP Apr 2024 1.000 call
See More Headlines
Receive NRXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NRXP
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Net Income
$-39,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.11 per share

Miscellaneous

Free Float
72,961,000
Market Cap
$43.62 million
Optionable
Optionable
Beta
0.99
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Jonathan C. Javitt M.D. (Age 67)
    M.P.H., Co-Founder, Chief Scientist Officer & Chairman
    Comp: $873.7k
  • Mr. Stephen H. Willard Esq. (Age 63)
    Acting Corporate Secretary, CEO & Director
    Comp: $501.19k
  • Dr. Riccardo Panicucci Ph.D. (Age 62)
    Chief Technology Officer
    Comp: $240k
  • Dr. Seth L. Van Voorhees Ph.D. (Age 63)
    Treasurer
    Comp: $399.96k
  • Mr. Richard Clavano Narido (Age 46)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Suzanne Messere
    Investor Relations
  • Dr. Philip T. Lavin Ph.D. (Age 77)
    Chief Methodologist
  • Dr. Dennis K. McBride Ph.D.
    Chief Strategy Officer & Senior Scientist
  • Mr. Matthew Patrick Duffy (Age 61)
    Chief Business Officer

NRXP Stock Analysis - Frequently Asked Questions

How have NRXP shares performed in 2024?

NRx Pharmaceuticals' stock was trading at $0.46 at the beginning of the year. Since then, NRXP stock has increased by 2.6% and is now trading at $0.4719.
View the best growth stocks for 2024 here
.

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,710,000 shares, an increase of 36.9% from the February 29th total of 2,710,000 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 6.0% of the company's stock are short sold.
View NRx Pharmaceuticals' Short Interest
.

When did NRx Pharmaceuticals' stock split?

NRx Pharmaceuticals's stock reverse split on Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What guidance has NRx Pharmaceuticals issued on next quarter's earnings?

NRx Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share guidance of -0.400--0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -.

Who are NRx Pharmaceuticals' major shareholders?

NRx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include AdvisorShares Investments LLC (0.75%), One Wealth Management Investment & Advisory Services LLC (0.16%), Bridgeway Capital Management LLC (0.14%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Aaron Gorovitz, Alessandra Daigneault, Chaim Hurvitz, Daniel C Javitt, Jonathan C Javitt, Patrick John Flynn, Robert Besthof, Stephen H Willard and Voorhees Seth Van.
View institutional ownership trends
.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRXP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners